Today, the increasing number of illicit internet pharmacies is a global phenomenon, however, the size of the online pharmaceutical market is still relatively unknown and the dubious quality of products is questionable and warrants investigation. Descriptive data from this black market channel are derived from studies analyzing the online availability of different medications procured over the internet and their methodology is quite heterogeneous. Our aim was to develop a comprehensive and specific risk assessment for selecting high patient safety risk medications from the online pharmaceutical market. A rapid tool was developed based upon the two quality and safety standard resolutions in pharmaceutical practice, published by the European Directorate for the Quality of Medicines, and was illustrated on eye drops. We developed five dimensions in support of the risk assessment including intrinsic, extrinsic and potential risks of counterfeiting. The five criteria were integrated in a comprehensively weighted risk-scoring format. The probability of procuring the product from the internet was also assessed based on the number of relevant links within the first twenty search engine results and the cost of the products. With the application of the tool a dorzolamide & timolol combination eye drop represented the highest overall patient safety risk score. In consideration of our literature review of the past 20 years, there is no current, standardized methodology to effectively identify pharmaceutical products associated with high patient safety risks. Notably, the fully comprehensive analysis of the internet pharmaceutical market and the test purchase of all online available medicines is unrealistic. Therefore, we developed a method to aid online surveillance researches and targeted international organizational led joint actions against the uncontrolled sale of falsified and substandard medications (e.g.: Operation Pangea).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783221PMC
http://dx.doi.org/10.1016/j.jsps.2020.10.018DOI Listing

Publication Analysis

Top Keywords

pharmaceutical market
12
patient safety
12
online pharmaceutical
8
risk assessment
8
high patient
8
safety risk
8
risk
5
internet
5
online
5
pharmaceutical
5

Similar Publications

Background: Few clinical studies of atrial fibrillation (AF) have focused on Asian patients; data are lacking on current mapping and ablation strategies in the Asia Pacific region (APAC).

Objective: The HD Mapping Observational Study (NCT04022954) was designed to characterize electroanatomic mapping (EAM) with market-released high-density mapping (HDM) catheters in subjects with AF in APAC.

Methods: Subjects undergoing HDM and indicated for radiofrequency ablation (RFA) to treat AF were prospectively enrolled in APAC.

View Article and Find Full Text PDF

Engineering vaginal film platform for mucoadhesion and sustained drug release for HIV-1 prevention.

J Control Release

January 2025

Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA; Magee-Womens Research Institute, Pittsburgh, PA, USA; Department of Obstetrics, Gynecology & Reproductive Sciences, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address:

User adherence contributes to the effectiveness of topical pre-exposure prophylactic products designed to protect against human immunodeficiency virus type 1 (HIV-1) infection. Long-acting approaches that do not require daily or coitally-dependent use could potentially improve user adherence. This study aims to develop a long-acting vaginal film to deliver an integrase inhibitor, MK-2048, for prevention of HIV-1 infection.

View Article and Find Full Text PDF

In 2021, the sole paragraph of article 40 of the Industrial Property Law (LPI) was declared unconstitutional. As a result, some companies filed lawsuits seeking an extension of the term of validity of their pharmaceutical patents. This article aims to estimate the possible economic consequences of the extension of the term of patents in spending on medicines for centralized procurement and the private market.

View Article and Find Full Text PDF

Functional proteins/peptides targeting to clear Amyloid-β for Alzheimer's disease therapy.

Chembiochem

January 2025

China Pharmaceutical University, Department of Pharmaceutical Science, #639 Longmian Dadao, Jiangning District, 211198, Nanjing, CHINA.

Alzheimer's disease (AD) is a significant neurodegenerative disorder primarily affecting individuals over the age of 65. It is characterized by impairments in memory, thinking, analytical judgment, visuospatial recognition, and mood. In recent years, the development of protein and peptide drugs targeting amyloid-beta (Aβ) has gained momentum, with several therapies entering clinical trials and even receiving marketing approval.

View Article and Find Full Text PDF

Value-Based Pricing for Drugs With Uncertain Clinical Benefits.

Health Econ

January 2025

Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.

Policymakers can use cost-effectiveness analysis to set value-based prices (VBP) for new pharmaceuticals. However, the uncertainty of investigational drug benefits complicates this pricing strategy. Such complexity stems from decision-makers' risk aversion and the potential change in the estimated value with emerging evidence.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!